A remarkable characteristic of majority of cancer cells is that, they fail to undergo apoptosis,
which in turn confers them a survival advantage over normal cells. Targeted cancer therapy …

Targeting the Bcl-2 : Current Opinion in Oncology Targeting the Bcl-2 : Current Opinion in
Oncology Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts …

Apoptosis deficiency is one of the most important features observed in neoplastic diseases.
The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis …

Escape from apoptosis is often a hallmark of cancer cells, and is associated to
chemotherapy resistance or tumor relapse. Proteins from the Bcl-2 family are the key …

Bcl-2 family proteins are key regulators of programmed cell death or apoptosis that is
implicated in many human diseases, particularly cancer. In recent years, they have attracted …

Bcl-2 is the founding member of a large family of proteins that regulate cell survival and cell
death. Since its discovery in B-cell lymphomas over 30 years ago, research on the biological …

Apoptosis (or programmed cell death) is a genetically controlled “cell suicide” pathway
which plays an essential role in deleting excess, unwanted or damaged cells during …

Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2‐proteins are
highly promising targets for the development of novel anticancer treatments. To this end …

Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell
lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 …

The BCL-2 gene was first cloned in 1985 from the t (14; 18) chromosomal translocation
found in nearly all follicular lymphomas. BCL-2 is understood to have a central role in …